Category: Generics (U.K.)
-
EPO Board of Appeal revokes Novo Nordisk’s cardiovascular semaglutide patent; generics could enter EU as early as 2031
The Board found the claims lacked priority, so a clinical study publication destroyed novelty, leaving Ozempic and Wegovy potentially vulnerable to competition earlier than expected.
-
Post-judgment cleanup orders in UK pharma cases: no disgorgement of Bayer profits; Teva, Glenmark, Generics (UK) recover two thirds of costs
AstraZeneca must reimburse two thirds of the costs of an unsuccessful case Teva, Glenmark and Generics (UK). Separately, Bayer does not have to disgorge profits to Sandoz.